ADVANCED THERAPIES XCHANGE
WEST COAST
MARCH 28, 2022
Welcome to hubXchange’s Hybrid Advanced Therapies Xchange 2022, West Coast, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in cell and gene therapeutics.
Discussion topics will cover Cell Tx Development, Gene Tx Development, C&G Tx Bioprocessing and C&G Tx Manufacturing.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Please note this is a HYBRID meeting. Participants can join in-person and virtually. All Covid protocols will be adhered to.
Venue Details: DoubleTree by Hilton San Francisco Airport Hotel, 835 Airport Boulevard, Burlingame CA 94010-9949
Cell Tx Development
Opening Address & Keynote Presentation: Outsmarting Complex Diseases with Intelligent Medicines
- Discuss how complex gene circuits can be used to generate smarter cell therapies that overcome fundamental disease challenges
- Explore the use of gene circuits within cell therapies to increase efficacy and specificity
- Demonstration of gene circuit application: FLT3 OR CD33 NOT EMCN CAR-NK cell therapy for acute myeloid leukemia (AML)
Director of Research, Senti Biosciences
Brian Garrison, PhD, is Director of Research at Senti Bio, where he leads development of logic gated CAR-NK cell therapies for cancer, and is driven by the belief that introduction of logic gating into cell therapies will ultimately be transformative for cancer patients in need. Dr. Garrison has been helping develop novel technologies and therapies at Senti for over 5 years, after having completed 2 postdoctoral fellowships at Harvard University focused on stem cell biology and leukemia, and a PhD in human gene therapy from Stanford University.
Cell therapy for solid tumors: challenges and opportunities
- Finding the tumor
- Trafficking CAR T cells to the tumor site
- Overcoming hostile tumor microenvironment
- Production logistics and financial accessibility issues
Chief Cellular Therapy Officer
Nurix Therapeutics
Michael Lotze has served as Chief Cellular Therapy Officer of Nurix since June 2020. He is a leading clinician scientist with more than 30 years of experience in immunology and clinical medicine, dedicating his efforts to the advancement of translational research, particularly in immunotherapy for cancer including dendritic cell, T cell, and cytokine therapies. He is the co-inventor of multiple patents in dendritic cell vaccines and antigen discovery, and tumor infiltrating lymphocyte therapy. He previously held leadership roles at Iovance Biotherapeutics and GlaxoSmithKline. Prior to joining Nurix, Michael served as professor of surgery, immunology, and bioengineering, vice chair of research at the University of Pittsburgh Medical Center Hillman Cancer Center.
Over the course of his career, he has authored more than 500 publications and several books. Michael holds an M.D. from Northwestern University and completed his postdoctoral training at the National Cancer Institute.
- Do you use only mouse antibodies in your R&D models or do you consider other species?
- Is there an advantage to working with human antibodies raised in human biology?
- When to conduct antibody discovery vs using off-the-shelf solutions?
Director, Business Development, Rapid Novor
Anthony has been heading the business development at Rapid Novor for nearly 5 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™and NovorIg™ platforms with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a maker and in his spare time takes advantage of the Toronto HackLab to do biological research and other engineering projects
Networking Lunch
Next-Generation Engineering Approaches
- What are the most promising approaches to logic-gating cell therapy responses?
- Advantages and disadvantages of building tunable cell therapies?
- What technical hurdles must be overcome to implementation of more advanced synthetic biology approaches in cell therapy?
Director of Research, Senti Biosciences
Brian Garrison, PhD, is Director of Research at Senti Bio, where he leads development of logic gated CAR-NK cell therapies for cancer, and is driven by the belief that introduction of logic gating into cell therapies will ultimately be transformative for cancer patients in need. Dr. Garrison has been helping develop novel technologies and therapies at Senti for over 5 years, after having completed 2 postdoctoral fellowships at Harvard University focused on stem cell biology and leukemia, and a PhD in human gene therapy from Stanford University.
4:20 – 5:20pm
Beyond CART: Alternative cell modalities
- What are the pros and cons of potential alternatives to T cells?
- What technical hurdles must be overcome for development of these alternatives?
- Can specific cell types be matched with given indications?
- What drives selection of the best binding moiety for a chimeric receptor?
- In vivo CAR-T cell therapies
CSO
Nkarta Therapeutics
James Trager joined Nkarta in 2016 and leads all new product discovery efforts. James is deeply versed in the development and application of cellular therapies for cancer. He previously served as Vice President of Research and Development at Dendreon, where he was responsible for product development, clinical immunology, analytical development, and process automation, supporting the late stage development of sipuleucel-T through clinical study, approval, and commercialization. Prior to Dendreon, James was a Senior Scientist at Geron, where he was part of the team that cloned human telomerase, and later established a Quality Control function to enable the manufacture and clinical development of a telomerase inhibitor.
